Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,104 public trials 2,042 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

NCT01682616

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations
  • Moores Cancer Center at UC San Diego /ID# 70398 La Jolla, California, United States
  • Northwestern University Feinberg School of Medicine /ID# 71593 Chicago, Illinois, United States
  • North Shore University Hospital /ID# 71813 New Hyde Park, New York, United States
  • Duke Cancer Center /ID# 71393 Durham, North Carolina, United States
View Trial Details
Completed

Corneal Toxicity in Patients Treated by Belantamab Mafodotin

NCT05887206

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • CHU Dijon Dijon, France
  • CHU de Limoges - Hôpital Dupuytren Limoges, France
  • HCL- Croix Rousse Lyon, France
  • Clinique Monticelli-Vélodrome Marseille, France
View Trial Details
Completed

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

NCT03311412

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
Locations
  • South Texas Accelerated Research Therapeutics (START) Midwest Grand Rapids, Michigan, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
  • NEXT Oncology San Antonio, Texas, United States
  • Princess Margaret Cancer Centre Toronto, Ontario, Canada
View Trial Details
Completed

A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment

NCT01596621

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • Teva Investigational Site 001 Beijing, China
  • Teva Investigational Site 026 Beijing, China
  • Teva Investigational Site 022 Beijing, China
  • Teva Investigational Site 004 Beijing, China
View all 27 locations
View Trial Details
Completed

ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy

NCT04121507

Conditions
Aggressive Non-hodgkin Lymphoma (aNHL), Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • HELIOS Klinik Berlin-Buch, Klinik für Hämatologie und Stammzelltransplantation Berlin, Brandenburg, Germany
  • Klinikum Augsburg, Medizinische Klinik II Augsburg, Germany
  • Medizinisches Universitätsklinikum Bochum, Germany
  • Klinikum Chemnitz gGmbH Chemnitz, Germany
View all 13 locations
View Trial Details

Related conditions